focus
Editor’s note: A recording of the event is embedded below.
Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines? Join leading experts to discuss the impact on the industry and patients.
advertisement
Sponsor introduction
- Thomas Newcomer, vice president and head of U.S. market access, Samsung Bioepis (sponsor)
Featured speakers
- Chris M. Brown, president, McAteer
- Michael Gonzales, independent health care consultant, Michael Gonzales, LLC; former national and regional account director, AbbVie
- Fran Gregory, MBA, PharmD, vice president of emerging therapies, Cardinal Health
- Ed Silverman, Pharmalot columnist, senior writer, STAT (moderator)
Sponsored By
Previous article：
STAT Report: Patient voices and perspectives
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
